MX2018007681A - An oral osmotic pharmaceutical composition of vildagliptin. - Google Patents
An oral osmotic pharmaceutical composition of vildagliptin.Info
- Publication number
- MX2018007681A MX2018007681A MX2018007681A MX2018007681A MX2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A
- Authority
- MX
- Mexico
- Prior art keywords
- vildagliptin
- pharmaceutical composition
- salt
- surrounding
- osmotic pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1:1 to about 1:5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat. Also provided is process of preparing such compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4891MU2015 | 2015-12-28 | ||
PCT/IB2016/057975 WO2017115252A1 (en) | 2015-12-28 | 2016-12-23 | An oral osmotic pharmaceutical composition of vildagliptin |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007681A true MX2018007681A (en) | 2018-11-14 |
Family
ID=57966046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007681A MX2018007681A (en) | 2015-12-28 | 2016-12-23 | An oral osmotic pharmaceutical composition of vildagliptin. |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20180092981A (en) |
BR (1) | BR112018013195A2 (en) |
MX (1) | MX2018007681A (en) |
PH (1) | PH12018550075A1 (en) |
RU (1) | RU2706706C1 (en) |
WO (1) | WO2017115252A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19616486C5 (en) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Method for lowering the blood glucose level in mammals |
CO5150173A1 (en) | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
AU2003262059A1 (en) | 2002-09-11 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
KR101368525B1 (en) | 2005-09-20 | 2014-03-06 | 노파르티스 아게 | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
MX2010009731A (en) * | 2008-03-04 | 2010-09-30 | Merck Sharp & Dohme | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor. |
PL2578208T3 (en) | 2011-10-06 | 2014-10-31 | Sanovel Ilac Sanayi Ve Ticaret As | DPP-IV inhibitor solid dosage formulations |
JP2015526456A (en) | 2012-08-23 | 2015-09-10 | カーディオリンクス・アーゲーCardiolynx Ag | Extended release composition of aminoalkyl nitrate |
-
2016
- 2016-12-23 MX MX2018007681A patent/MX2018007681A/en unknown
- 2016-12-23 WO PCT/IB2016/057975 patent/WO2017115252A1/en active Application Filing
- 2016-12-23 BR BR112018013195A patent/BR112018013195A2/en not_active Application Discontinuation
- 2016-12-23 KR KR1020187016451A patent/KR20180092981A/en unknown
- 2016-12-23 RU RU2018120202A patent/RU2706706C1/en not_active IP Right Cessation
-
2018
- 2018-06-01 PH PH12018550075A patent/PH12018550075A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2706706C1 (en) | 2019-11-20 |
PH12018550075A1 (en) | 2019-01-28 |
KR20180092981A (en) | 2018-08-20 |
WO2017115252A1 (en) | 2017-07-06 |
BR112018013195A2 (en) | 2018-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015184127A3 (en) | Stable cannabinoid formulations | |
WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
EP3590498A4 (en) | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration | |
CL2016002560A1 (en) | Oral solid pharmaceutical dosage form comprising siponimod, a moisture protective agent and optionally a pharmaceutical excipient; Preparation procedure | |
DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
MX2018012618A (en) | Oral pharmaceutical compositions of mesalazine. | |
PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
MX2017003561A (en) | Compositions and methods for cannabinoid coatings for use in drug delivery. | |
WO2015125152A3 (en) | Pharmaceutical compositions of asenapine | |
WO2019194773A3 (en) | The combination comprising linagliptin and metformin | |
WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
PH12016500693A1 (en) | Slow-release solid oral compositions | |
EP3648745A4 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
MX2021014830A (en) | CONJUGATES OF <i>Ï</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS. | |
MX2015010486A (en) | Chewable composition for oral administration and process for preparing thereof. | |
WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
WO2016167605A3 (en) | Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine | |
PH12018550075A1 (en) | An oral osmotic pharmaceutical composition of vildagliptin | |
CY1125762T1 (en) | NEW BY THE MOUTH PREPARATION VELINOSTATIS | |
EA201991286A1 (en) | A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN | |
WO2018069805A3 (en) | Method for preparation of liquid oral composition of l-thyroxin | |
EP3898596A4 (en) | Pharmaceutical compound, the method of its making and use as medicinal agent | |
PH12016502527A1 (en) | Stabilized desmopressin | |
WO2019240700A3 (en) | Oral pharmaceutical compositions of mesalazine | |
WO2016187595A3 (en) | Oral pharmaceutical composition of methylergonovine |